290 related articles for article (PubMed ID: 31822200)
21. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
[TBL] [Abstract][Full Text] [Related]
22. Transitioning historically inpatient chemotherapy regimens for hematologic malignancies to the ambulatory care setting.
Moore DC; Arnall JR; Plesca DC
Am J Health Syst Pharm; 2018 Nov; 75(22):1824-1830. PubMed ID: 30131323
[No Abstract] [Full Text] [Related]
23. Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities.
Tanaka N; Imai Y; Yoshinaga K; Shiseki M; Tanaka J
Ann Hematol; 2020 Nov; 99(11):2577-2586. PubMed ID: 32945942
[TBL] [Abstract][Full Text] [Related]
24. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
25. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
[TBL] [Abstract][Full Text] [Related]
26. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
28. Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment.
Herold M; Hieke K
Value Health; 2003; 6(2):167-74. PubMed ID: 12641867
[TBL] [Abstract][Full Text] [Related]
29. Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis of lymphoma: a retrospective study of a large cohort of major lymphoma subtypes in Spain.
Bosch X; Sanclemente-Ansó C; Escoda O; Monclús E; Franco-Vanegas J; Moreno P; Guerra-García M; Guasch N; López-Soto A
BMC Cancer; 2018 Mar; 18(1):276. PubMed ID: 29530002
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
31. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
[TBL] [Abstract][Full Text] [Related]
32. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
[TBL] [Abstract][Full Text] [Related]
33. Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States?
Hopson S; Casebeer A; Stemkowski S; Antol DD; Tao Z; Howe A; Patton J; Small A; Masaquel A
J Med Econ; 2018 Feb; 21(2):152-162. PubMed ID: 28945163
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].
Malliti M; Junot H; Fievet MH; Gabarre J; Taright N; Vernant JP; Thuillier A
Ann Med Interne (Paris); 2003 May; 154(3):139-47. PubMed ID: 12910040
[TBL] [Abstract][Full Text] [Related]
35. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
36. Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment.
Clemmons AB; Anderegg S
J Oncol Pharm Pract; 2017 Jul; 23(5):384-388. PubMed ID: 27000280
[TBL] [Abstract][Full Text] [Related]
37. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.
Lamar ZS; Dothard A; Kennedy L; Isom S; Robinson M; Vaidya R; Hurd D; McClain D; Lesser G
Leuk Lymphoma; 2018 Aug; 59(8):1871-1877. PubMed ID: 29252084
[TBL] [Abstract][Full Text] [Related]
38. Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.
Floeter AE; Patel A; Tran M; Chamberlain MC; Hendrie PC; Gopal AK; Cassaday RD
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):225-230. PubMed ID: 28169156
[TBL] [Abstract][Full Text] [Related]
39. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
[TBL] [Abstract][Full Text] [Related]
40. Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis.
Baltin CT; Wulf C; Rongisch R; Lehmann C; Wingen-Heimann S; Eisenmenger N; Bonn J; Fabri M; von Stebut E; Cornely OA; Kron F
J Infect Public Health; 2023 Jun; 16(6):955-963. PubMed ID: 37099955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]